Showing 1,095 results

Filters Content type: News, Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

New & experimental hepatitis C treatment

Sofosbuvir + GS-5816 for 12 weeks shows high HCV cure rates, but 8 weeks is less effective for some patients

News
19 November 2014
Hepatitis C treatment

NHS asks Nice to delay ground-breaking hepatitis C drug

Editor's pick
Channel 4 News (blog)
19 November 2014
New & experimental hepatitis C treatment

European Commission Grants Marketing Authorization for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir)

Editor's pick
Gilead press release
19 November 2014
Hepatitis C treatment

Practical steps to eliminating hepatitis C: a consensus for London

Editor's pick
London Joint Working Group on Substance Use and Hepatitis C
17 November 2014
Hepatitis C treatment

Interim Revision of Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents

Editor's pick
AidsInfo
17 November 2014
Hepatitis C treatment

Merck's grazoprevir/elbasvir combo shows high cure rates, including for people with cirrhosis and HIV/HCV co-infection

News
13 November 2014
Hepatitis C treatment

Sofosbuvir/ledipasvir and AbbVie 2D regimen cure most people with HCV genotype 4

News
13 November 2014
Hepatitis C treatment

Sofosbuvir/ledipasvir with ribavirin is highly effective for people with decompensated cirrhosis

News
12 November 2014
Hepatitis C treatment

New HCV drugs pass muster in real world

Editor's pick
MedPage Today
11 November 2014
Hepatitis C treatment

Sustained virological response to hepatitis C treatment reduces mortality, liver cancer and liver transplants

News
10 November 2014
New & experimental hepatitis C treatment

Sofosbuvir/ledipasvir cures nearly all genotype 1 HCV for people with HIV co-infection

News
10 November 2014
Hepatitis C treatment

Olysio (simeprevir) approved for use in combination with sofosbuvir

Editor's pick
Johnson & Johnson press release
7 November 2014
Hepatitis C treatment

Bristol-Myers Squibb announces HCV global access plans

Editor's pick
Bristol-Myers Squibb press release
3 November 2014
Hepatitis C treatment

Australia's rejection of costly new treatment sofosbuvir a 'death sentence for for Hepatitis C sufferers'

Editor's pick
ABC Online
27 October 2014
New & experimental hepatitis C treatment

AbbVie 3D HCV regimen well-tolerated in PEARL trials

News
24 October 2014
Hepatitis C treatment

Ireland: Hepatitis C drug to be made available

Editor's pick
The Irish Times
22 October 2014
Hepatitis C treatment

Advocates Criticize Plans to Restrict N.Y. Hepatitis C Drugs

Editor's pick
Poz magazine news
22 October 2014
Hepatitis C treatment

Unique 'pay if you clear' proposal for new hepatitis drug

Editor's pick
BBC
15 October 2014
Hepatitis C treatment

As Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles

Editor's pick
Forbes
10 October 2014
New & experimental hepatitis C treatment

U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

Editor's pick
Gilead press release
10 October 2014
Hepatitis C treatment

Thousands of Hep C patients in Alexandria wait in long lines to receive Sovaldi

Editor's pick
Egypt Independent
10 October 2014
Hepatitis C treatment

Sovaldi ‘unaffordable’ says NHS documents

Editor's pick
Pharmafile
8 October 2014
Hepatitis C treatment

CVS: One In 12 Hepatitis C Patients Not Adhering To $1,000/Day Pill

Editor's pick
Forbes
7 October 2014
Hepatitis C treatment

Most Spanish patients coinfected with HIV/HCV called difficult to cure

Editor's pick
Healio
7 October 2014